Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic lysis therapy in retinal vascular occlusions]

L O Hattenbach1

  • 1Klinik für Augenheilkunde, Klinikum, Johann Wolfgang Goethe-Universität Frankfurt/Main.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|October 23, 1998
PubMed
Summary

Fibrinolytic therapy, using low-dose recombinant tissue plasminogen activator (rt-PA), shows promise for retinal vessel occlusions like central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO). Careful patient selection is crucial due to bleeding risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.

European journal of ophthalmology·2022
Same author

[Regression of idiopathic epiretinal membrane-Case report and consideration of the possible mechanism].

Die Ophthalmologie·2022
Same author

[Real-time optical coherence tomography-assisted high-precision vitreoretinal surgery in the clinical routine].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2019
Same author

[Preoperative assessment of topographic features in macular pucker using high-definition optical coherence tomography].

Klinische Monatsblatter fur Augenheilkunde·2009
Same author

[Selective thrombophilia screening of young patients with retinal vein occlusion].

Klinische Monatsblatter fur Augenheilkunde·2009
Same author

[Bilateral influenza-triggered panuveitis and subsequent therapy with amantadine and hyperimmunoglobulins].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2004

Area of Science:

  • Ophthalmology
  • Vascular Medicine
  • Pharmacology

Background:

  • Fibrinolytic agents are standard for major vessel occlusions.
  • Retinal vessel occlusions (RVO) may benefit from early blood flow restoration.
  • Systemic fibrinolysis carries a hemorrhagic risk, necessitating careful treatment selection for RVO.

Purpose of the Study:

  • To review studies on fibrinolytic therapy for retinal vessel occlusion.
  • To evaluate the safety and efficacy of thrombolytic regimens in large-scale trials for myocardial infarction and stroke.
  • To report on the use of low-dose rt-PA for retinal artery and vein occlusions.

Main Methods:

  • Review of existing literature on fibrinolysis in retinal vessel occlusion.
  • Analysis of large-scale trials for myocardial infarction and ischemic stroke.

Related Experiment Videos

  • Pilot study using low-dose rt-PA (50 mg) with intravenous heparin in CRAO and RVO patients.

    • Main Results:

    • Low-dose fibrinolytic regimens are suggested to minimize bleeding complications.
    • Low-dose rt-PA (50 mg) frontloaded with heparin appears a reasonable option for specific CRAO/RVO cases.
    • Treatment is limited to patients with recent symptoms and severe visual loss, with numerous contraindications.

    Conclusions:

    • Low-dose fibrinolysis is the preferred approach for retinal vessel occlusion.
    • Low-dose rt-PA offers a potential treatment option for selected CRAO and RVO patients.
    • Controlled clinical trials are necessary to confirm the benefits of thrombolysis in severe RVO due to poor prognosis.